GlassScriptPhysician profile
Maged M Costantine
NPI 1386855674
$36,572.20
in general payments reported to CMS, 2019-2025
7 companies · $5,922 in 2025
The $5,922 reported for 2025 was more than what 95% of Maternal & Fetal Medicine providers received nationally (typical 2025 total: $55.21).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,200 · 2022: $1,200 · 2023: $25K · 2024: $3,400 · 2025: $5,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Travel and Lodging: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,850.00 |
| Travel and Lodging | $322.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $25,600.00 | 2022-2024 | |
| Eli Lilly and Company | $5,922.20 | 2025 | |
| Merck Sharp & Dohme LLC | $2,200.00 | 2024 | |
| Kyowa Kirin, INC. | $1,650.00 | 2023 | |
| Quidel Corporation | $1,200.00 | 2020 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Costantine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.